Mosaic ImmunoEngineering extends Oncotelic acquisition term sheet to June 30, 2025

Mosaic ImmunoEngineering Inc.

Binding term sheet for acquisition of Oncotelic's necroptosis cancer therapies and AI tech extended to June 30, 2025.
Original deal: $15M stock issuance at closing plus up to $15M milestone shares.
Extension allows more time for due diligence and drafting definitive agreements; no guarantee a deal will close.
Parties continue negotiating; prior expiration was December 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.